These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 18520810)
1. Image of the month. Rash in a patient treated with pemetrexed for relapsed non-small cell lung cancer. Declercq I; Lievens Y; Verbeken E; Vansteenkiste J J Thorac Oncol; 2008 Jun; 3(6):662-3. PubMed ID: 18520810 [No Abstract] [Full Text] [Related]
2. Pemetrexed: new indication. Untreated non-small cell lung cancer: just another cytotoxic drug. No better than the gemcitabine-cisplatin combination with a different safety profile, as is the case for other cytotoxic drugs. Prescrire Int; 2009 Jun; 18(101):114. PubMed ID: 19637425 [No Abstract] [Full Text] [Related]
4. Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression. Igawa S; Ryuge S; Wada M; Otani S; Maki S; Takakura A; Katono K; Sasaki J; Sato Y; Masuda N Chemotherapy; 2012; 58(4):313-20. PubMed ID: 23147191 [TBL] [Abstract][Full Text] [Related]
5. Pemetrexed: current development and future directions in thoracic cancers. Manegold C Suppl Tumori; 2002; 1(4):S11-2. PubMed ID: 12415805 [No Abstract] [Full Text] [Related]
6. A case of pemetrexed-induced acute lung injury in non-small cell lung cancer. Kim HO; Lee SY; Shim JJ; Kang KH; Shin BK J Thorac Oncol; 2010 Mar; 5(3):401-2. PubMed ID: 20186027 [No Abstract] [Full Text] [Related]
7. Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer. Shimizu T; Nakanishi Y; Nakagawa Y; Tsujino I; Takahashi N; Nemoto N; Hashimoto S Anticancer Res; 2012 Oct; 32(10):4589-96. PubMed ID: 23060591 [TBL] [Abstract][Full Text] [Related]
8. Painful generalized erythematous patches: a severe and unusual cutaneous reaction to pemetrexed. Vitiello M; Romanelli P; Kerdel FA J Am Acad Dermatol; 2011 Jul; 65(1):243-4. PubMed ID: 21679840 [No Abstract] [Full Text] [Related]
9. [Role of pemetrexed in the treatment of advanced non-small-cell lung cancer: news from ASCO, 2008]. de Marinis F; Ricciardi S Tumori; 2008; 94(5):suppl 3-13. PubMed ID: 19112963 [No Abstract] [Full Text] [Related]
11. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis. Pujol JL; Paul S; Chouaki N; Peterson P; Moore P; Berry DA; Salzberg M J Thorac Oncol; 2007 May; 2(5):397-401. PubMed ID: 17473654 [TBL] [Abstract][Full Text] [Related]
12. The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer. Kim YS; Sun JM; Ahn JS; Ahn MJ; Park K Lung Cancer; 2013 Aug; 81(2):231-5. PubMed ID: 23683535 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer. Sun JM; Lee KW; Kim JH; Kim YJ; Yoon HI; Lee JH; Lee CT; Lee JS Jpn J Clin Oncol; 2009 Jan; 39(1):27-32. PubMed ID: 18952704 [TBL] [Abstract][Full Text] [Related]
15. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. Sun JM; Han J; Ahn JS; Park K; Ahn MJ J Thorac Oncol; 2011 Aug; 6(8):1392-9. PubMed ID: 21716147 [TBL] [Abstract][Full Text] [Related]
16. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Ciuleanu T; Brodowicz T; Zielinski C; Kim JH; Krzakowski M; Laack E; Wu YL; Bover I; Begbie S; Tzekova V; Cucevic B; Pereira JR; Yang SH; Madhavan J; Sugarman KP; Peterson P; John WJ; Krejcy K; Belani CP Lancet; 2009 Oct; 374(9699):1432-40. PubMed ID: 19767093 [TBL] [Abstract][Full Text] [Related]
17. The place of pemetrexed in the management of non-small-cell lung cancer patients. Tomasini P; Greillier L; Khobta N; Barlesi F Expert Rev Anticancer Ther; 2013 Mar; 13(3):257-66. PubMed ID: 23477511 [TBL] [Abstract][Full Text] [Related]
18. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Adjei AA Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4276s-4280s. PubMed ID: 15217974 [TBL] [Abstract][Full Text] [Related]
19. Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study. Sun Y; Wu YL; Zhou CC; Zhang L; Zhang L; Liu XY; Yu SY; Jiang GL; Li K; Qin SK; Ma SL; Han L; Quinlivan M; Orlando M; Zhang XQ Lung Cancer; 2013 Feb; 79(2):143-50. PubMed ID: 23182660 [TBL] [Abstract][Full Text] [Related]
20. Vitamin supplementation in patients receiving pemetrexed for advanced non-small cell lung cancer. de Marinis F; Passaro A; Clarke S Lung Cancer; 2013 Dec; 82(3):511. PubMed ID: 24080011 [No Abstract] [Full Text] [Related] [Next] [New Search]